Mera Pharmaceuticals Inc. Announces Management Changes; Amends Articles of Incorporation
June 14, 2012
Share
Mera Pharmaceuticals Inc. announced that Effective June 15, 2012, Gregory F. Kowal resigned as Chief Executive Officer and Chief Financial Officer, Kenneth I. Crowder resigned as Chief Operating Officer of the company and elected Mr. Spaniak as President and Chief Executive Officer, Mr. Lawrence Wolfe as Vice President of Finance and Chief Financial Officer and Joyce Markley as Secretary. Messrs. Kowal, Crowder and Yamamoto have resigned as directors effective June 15, 2012. Messrs. Villari, Spaniak, Wolfe and Ms. Markley have been elected as directors. Mr. Kowal has, however, remained with the company as President of its continuing Hawaiian salt business.
On June 15, 2012, the company has amended its Articles of Incorporation to designate the Series C Convertible Preferred Stock.
Mera Pharmaceuticals, Inc. is a marine biotechnology company. The Company focuses on photobioreactor technology and owns intellectual property dedicated to the culture of microalgae for biofuel or nutriceutical production. The Company manufactures natural astaxanthin from Haematococcus pluvialis microalgae. Through its research and development, the Company has formulated AstaFactor, an astaxanthin supplement with antioxidant and anti-inflammatory activity, which is available in three formulations, such as rejuvenating formula, sports formula and salmon essentials, such as natural astaxanthin combined with a blend of fish and salmon oil. The Company also produces sea salt products, such as gourmet salt and nigari. The gourmet salt includes Hawaiian Furikake, Hawaiian Furikake refillable grinder, Kona Sea Salt, Kona Sea Salt flake salt case, Kona Sea Salt grinder and Kona Sea Salt grinder case. The Company offers nigari in sizes ranging from one gallon to 250 gallons.
MERA PHARMACEUTICALS, INC. 
